Canada Begins Reviewing AstraZeneca's Coronavirus Vaccine, U.S. Study Still Not Restarted
Add Canada to the list of countries reviewing AstraZeneca's (NYSE: AZN) coronavirus vaccine, AZD1222, before the phase 3 clinical trial is complete. The European Medicines Agency is also conducting a rolling review of the vaccine. AstraZeneca can also submit preclinical animal safety data before the phase 3 data is ready to be submitted.